在高风险神经母细胞瘤中,由PRMT5驱动的持续癌症相关的替代RNA剪接事件
Laurel Tabe Bate-Eya1, Gulsah Albayrak1, Simon Mark Carr1
1Laboratory of Cancer Biology, Department of Oncology, University of Oxford, UK.
Molecular oncology
|July 18, 2024
概括
蛋白质氨酸甲基转移酶5 (PRMT5) 和E2F1在高风险神经母细胞瘤中过度表达,导致异常RNA拼接阻断细胞亡. 向PRMT5可能会恢复这些侵袭性癌症的亡敏感性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症遗传学 癌症遗传学
背景情况:
- 蛋白质氨酸甲基转移酶5 (PRMT5) 是一种在各种癌症中过度表达的关键瘤原因驱动剂.
- PRMT5调节转录因子E2F1,影响癌症的进展.
- 神经母细胞瘤 (NB) 是一种儿科癌症,在高风险病例中常常与预后不佳有关.
研究的目的:
- 研究PRMT5和E2F1在神经母细胞瘤中的作用.
- 了解高危神经母细胞瘤中PRMT5,E2F1和MYCN之间的关系.
- 探索异常RNA拼接对神经母细胞瘤中亡的影响.
主要方法:
- 在神经母细胞瘤患者样本中分析PRMT5和E2F1的表达.
- PRMT5,E2F1和MYCN基因放大之间的相关性研究.
- 研究MYCN对剪接因子基因表达的影响.
- 评估PRMT5抑制或E2F1失活对RNA剪接和亡的影响.
主要成果:
- 增加PRMT5和E2F1表达与神经母细胞瘤的预后不佳和MYCN放大有关.
- MYCN驱动拼接因子的表达,导致不受管制的替代RNA拼接.
- 这种异常的拼接程序抑制了神经母细胞瘤细胞中的亡.
- 药理上的PRMT5抑制或E2F1失活恢复了正常的拼接和诱导的亡.
结论:
- 由PRMT5,E2F1和MYCN驱动的异常RNA拼接有助于高风险神经母细胞瘤中细胞灭亡抵抗.
- PRMT5被确定为高风险神经母细胞瘤的有前途的治疗标.
- 通过抑制PRMT5恢复正常的拼接提供了一种潜在的策略,可以使神经母细胞瘤细胞重新敏感到亡.
相关概念视频
RNA Splicing
56.3K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.3K
Alternative RNA Splicing
21.1K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.1K
Rous Sarcoma Virus (RSV) and Cancer
5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.0K
Non-LTR Retrotransposons
11.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K
Nonsense-mediated mRNA Decay
10.6K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
10.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


